Nathalie Lambot has been graduated as pharmacist in from the Free University of Brussels, and has had a PhD in Biomedical Sciences from the Free University of Brussels. After having worked several years in CRO and pharmaceutical company in international regulatory affairs, Nathalie Lambot has joined in January 2013 pharma.be, the Belgian association of innovative (bio) pharmaceutical industry, as expert in Public Health – Clinical Trials & Regulatory Affairs.
MEET NATHALIE LAMBOT @ #KFG2019
Nathalie Lambot will present a lecture in the TEST session of the programme, together with Christophe Lahorte.
"Clinical Trials in Belgium: How innovation will drive the future?"
Belgium constitutes an unique health ecosystem in which clinical research can thrive. Thanks to a shared vision and common focus on solutions between the regulators, the industry, the researchers and the government, Belgium has been able to put itself on the map as one of the preferred locations for conducting trials in Europe (and even around the world). As a result, Belgium is systematically among the three countries in the clinical trials applications per millions inhabitants in the EU.
pharma.be, the Belgian association of the innovative (bio)pharmaceutical industry will present the results of its annual analysis of the Belgian footprint of clinical trials conducted with Deloitte. This analysis puts the Belgian landscape in an European perspective, and highlights the strengths of the country, which explain its competitive position about clinical trials, as well as the challenges and the opportunities for the country.
The Federal Agency for Medicines and Health Products (FAMHP) who is the Belgian competent authority in charge of the evaluation and approval of clinical trials conducted in Belgium will present an overview of the key activities and ongoing projects of it’s Innovation Office at national and EU level. The key mission of the FAMHP’s Innovation Office is to facilitate the translation of innovative scientific advances into new medicines and healthcare products meeting adequate standards and by doing so to accelerate patients’ access to promising new therapies and to contribute to the vibrant Belgian health ecosystem.